Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers taliglucerase alfa for injection, which is marketed under the ELELYSO brand name, as an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in Phase III clinical trial to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1 that is in Phase II clinical trial to treat cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase II clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Carmiel, Israel.
http://www.priceseries.com/trade/PLX-Protalix-BioTherapeutics-Inc-stock-gains-33-percent-a-Trade-Record-by-priceSeries-2019122720200114.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments